Sort
51,593 grants matching “hepatitis”
Phase I Trials of Anti-Cancer Agents
$754,879Michael R Grever · Ohio State University · U01 · FY2013 · CA
The Progression of Hepatitis C Among IDUs
$754,753Johns Hopkins University · R01 · FY2005 · DA
Generating Exogenic Organs for Transplantation without the Use of Immunosuppression
$754,411Clifford J. Steer · University Of Minnesota · R01 · FY2024 · AI
NIH Director's Pioneer Award
$754,346Nathan D Wolfe · University Of California Los Angeles · DP1 · FY2007 · OD
Immune function and the risk of cvd among HIV infected and uninfected veterans
$754,326Matthew S Freiberg · Vanderbilt University · R01 · FY2014 · HL
Role of the innate immune defenses in viral infections
$754,276Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK
Immunology of Acute and Chronic Viral Hepatitis
$754,276Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK
Next-generation human liver gene therapy
$754,269Holger Willenbring · University Of California, San Francisco · DP1 · FY2024 · DK
HEPATITIS C IN NEW IDUS: IMPLICATIONS FOR HIV PREVENTION
$754,232New York Academy Of Medicine · R01 · FY2003 · DA
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
$754,173David C. Johnson · Oregon Health & Science University · R01 · FY2022 · AI
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
$754,173David C. Johnson · Oregon Health & Science University · R01 · FY2021 · AI
Hepatitis B Clinical Research Network - Data Coordinating Center
$754,082Steven H. Belle · University Of Pittsburgh At Pittsburgh · U01 · FY2013 · DK
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)
$754,049Heidi M. Crane · University Of Washington · U24 · FY2020 · DA
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)
$754,049Heidi M. Crane · University Of Washington · U24 · FY2021 · DA
Mechanism of ultrasound neuromodulation effects on glucose homeostasis and diabetes
$754,027Raimund Ingo Herzog · Yale University · R01 · FY2025 · DK
Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (KeY Treat) Study
$753,883Jennifer R Havens · University Of Kentucky · R01 · FY2023 · DA
The Progression of Hepatitis C Among IDUs
$753,773Johns Hopkins University · R01 · FY2004 · DA
Deep Phenotyping of Human Knockouts and Population Studies of the APOC3 Pathway
$753,746Danish Saleheen · University Of Pennsylvania · R01 · FY2017 · HL
Pharmacologic targeting of the UPR in obesity-linked liver dysfunction
$753,715Enrique Saez · Scripps Research Institute, The · R01 · FY2024 · DK
Impact of HCV Therapy on CNS Outcomes
$753,645Ajay R Bharti · University Of California, San Diego · R01 · FY2016 · DA
Alcohol Metabolism, Functional Consequence and Apoptosis Signaling Mechanism
$753,554Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2009 · AA
Molecular Mechanisms of Inflammation, Steatosis and Hepatic Insulin Resistance
$753,204Jerrold M Olefsky · University Of California, San Diego · R24 · FY2010 · DK
Inhaled Delivery of Vidaza for Targeted Epigenetic Lung Cancer Therapy
$752,970Steven A Belinsky · Lovelace Biomedical & Environmental Research Institute · R01 · FY2018 · CA
Technical Validation of MR Biomarkers of Obesity-Associated NAFLD
$752,932Scott B. Reeder · University Of Wisconsin-Madison · R01 · FY2019 · DK
Delivery of Addiction Treatment for Medicaid Enrollees with Serious Injection-Related Infections
$752,902Shashi Kapadia · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · DA